Drug safety under scrutiny for advanced pancreatic cancer patients

NCT ID NCT04889404

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study monitored the safety of LYNPARZA, a maintenance drug, in 130 patients with a specific type of advanced pancreatic cancer (BRCA-mutated) who had already finished platinum-based chemotherapy. The goal was to track and understand the side effects that occurred in real-world use after the drug was approved. Researchers specifically looked for serious side effects like bone marrow problems, lung disease, and new cancers.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Osaka, Lyn010001, D081FC00004, Japan
Research Site

Kanagawa, Lyn010003, D081FC00004, Japan
Research Site

Okayama, Lyn010004, D081FC00004, Japan
Research Site

Akita, Lyn010005, D081FC00004, Japan
Research Site

Niigata, Lyn010006, D081FC00004, Japan
Research Site

Shizuoka, Lyn010007, D081FC00004, Japan
Research Site

Niigata, Lyn010008, D081FC00004, Japan
Research Site

Tokyo, Lyn010009, D081FC00004, Japan
Research Site

Saitama, Lyn010010, D081FC00004, Japan
Research Site

Aichi, Lyn010011, D081FC00004, Japan
Research Site

Osaka, Lyn010012, D081FC00004, Japan
Research Site

Tokyo, Lyn010013, D081FC00004, Japan
Research Site

Nara, Lyn010014, D081FC00004, Japan
Research Site

Wakayama, Lyn010015, D081FC00004, Japan
Research Site

Miyagi, Lyn010016, D081FC00004, Japan
Research Site

Tokyo, Lyn010017, D081FC00004, Japan
Research Site

Osaka, Lyn010018, D081FC00004, Japan
Research Site

Gunma, Lyn010019, D081FC00004, Japan
Research Site

Hiroshima, Lyn010020, Japan
Research Site

Tochigi, Lyn010021, D081FC00004, Japan
Research Site

Numakunai, Lyn010022, D081FC00004, Japan
Research Site

Osaka, Lyn010025, D081FC00004, Japan
Research Site

Shizuoka, Lyn010026, D081FC00004, Japan
Research Site

Nagasaki, Lyn010027, D081FC00004, Japan
Research Site

Kumamoto, Lyn010028, D081FC00004, Japan
Research Site

Saitama, Lyn010029, D081FC00004, Japan
Research Site

Nagano, Lyn010031, D081FC00004, Japan
Research Site

Hyōgo, Lyn010032, D081FC00004, Japan
Research Site

Shimane, Lyn010033, D081FC00004, Japan
Research Site

Hyōgo, Lyn010034, D081FC00004, Japan
Research Site

Shizuoka, Lyn010035, D081FC00004, Japan
Research Site

Hyōgo, Lyn010036, D081FC00004, Japan
Research Site

Okayama, Lyn010038, D081FC00004, Japan
Research Site

Fukuoka, Lyn010041, Japan
Research Site

Hokkaido, Lyn010042, Japan
Research Site

Ehime, Lyn010044, Japan
Research Site

Osaka, Lyn010045, Japan
Research Site

Shizuoka, Lyn010047, Japan
Research Site

Tokyo, Lyn010050, Japan
Research Site

Aichi, Japan
Research Site

Chiba, Japan
Research Site

Fukuoka, Japan
Research Site

Gunma, Japan
Research Site

Hiroshima, Japan
Research Site

Hokkaido, Japan
Research Site

Hyōgo, Japan
Research Site

Ibaraki, Japan
Research Site

Kagawa, Japan
Research Site

Kanagawa, Japan
Research Site

Kyoto, Japan
Research Site

Nagano, Japan
Research Site

Nagasaki, Japan
Research Site

Nara, Japan
Research Site

Okayama, Japan
Research Site

Osaka, Japan
Research Site

Shizuoka, Japan
Research Site

Tokyo, Japan
Research Site

Tottori, Japan
Research Site

Toyama, Japan
Research Site

Yamagata, Japan

Conditions

Explore the condition pages connected to this study.

PANCREATIC NEOPLASMS